全文获取类型
收费全文 | 6754篇 |
免费 | 448篇 |
国内免费 | 108篇 |
专业分类
耳鼻咽喉 | 174篇 |
儿科学 | 87篇 |
妇产科学 | 42篇 |
基础医学 | 1076篇 |
口腔科学 | 84篇 |
临床医学 | 444篇 |
内科学 | 1389篇 |
皮肤病学 | 290篇 |
神经病学 | 499篇 |
特种医学 | 763篇 |
外科学 | 1003篇 |
综合类 | 24篇 |
一般理论 | 3篇 |
预防医学 | 118篇 |
眼科学 | 290篇 |
药学 | 446篇 |
中国医学 | 47篇 |
肿瘤学 | 531篇 |
出版年
2023年 | 51篇 |
2022年 | 147篇 |
2021年 | 261篇 |
2020年 | 146篇 |
2019年 | 209篇 |
2018年 | 212篇 |
2017年 | 183篇 |
2016年 | 310篇 |
2015年 | 408篇 |
2014年 | 443篇 |
2013年 | 486篇 |
2012年 | 728篇 |
2011年 | 688篇 |
2010年 | 431篇 |
2009年 | 327篇 |
2008年 | 393篇 |
2007年 | 434篇 |
2006年 | 354篇 |
2005年 | 312篇 |
2004年 | 235篇 |
2003年 | 196篇 |
2002年 | 157篇 |
2001年 | 26篇 |
2000年 | 22篇 |
1999年 | 18篇 |
1998年 | 25篇 |
1997年 | 21篇 |
1996年 | 16篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 8篇 |
1992年 | 7篇 |
1991年 | 5篇 |
1990年 | 6篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1969年 | 1篇 |
1965年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有7310条查询结果,搜索用时 15 毫秒
61.
Eliel Nham Joon Young Song Ji Yun Noh Hee Jin Cheong Woo Joo Kim 《Journal of Korean medical science》2022,37(47)
Since its first emergence in late 2019, severe acute respiratory syndrome coronavirus-2 has claimed more than 6.5 million lives worldwide and continues to infect hundreds of thousands of people daily. To combat this once-in-a-century disaster, several vaccines have been developed at unprecedented speeds. Novel vaccine platforms (messenger ribonucleic acid vaccines and adenoviral vector vaccines) have played a major role in the current pandemic. In Korea, six vaccines, including a domestically developed recombinant vaccine, have been approved. As in other countries, vaccines have been proven to be safe and highly effective in Korea. However, rare serious adverse events and breakthrough infections have undermined public trust in the vaccines, even while the benefits of vaccination far outweigh the risks. The rise of the omicron variant and the subsequent increase in excess mortality demonstrated that while vaccines are a key component of the pandemic response, it alone can fail without non-pharmaceutical interventions like masking and social distancing. The pandemic of coronavirus disease has revealed both the strengths and weaknesses of our healthcare system and pandemic preparedness. When the next pandemic arrives, improved risk communication and vaccine development should be prioritized. To enable timely vaccine development, it is essential to make strategic and sufficient investments in vaccine research and development. 相似文献
62.
Joon Hee Park Hyun Ji Bang Nak-Hyun Choi Eun-Jin Park 《The journal of advanced prosthodontics》2022,14(5):324
PURPOSEThe purpose of this study is to evaluate translucency and masking ability of translucent zirconia compared to conventional zirconia and lithium disilicate materials.MATERIALS AND METHODSThree types of zirconia blocks with different yttria contents (3Y, 4Y, 5.5Y) and LS blocks (Rosetta SM) were used. Ten specimens for each group were fabricated with 10 mm diameter, with both 0.8 mm and 1.5 mm thicknesses (± 0.02 mm). All groups of zirconia specimens were sintered and polished according to the manufacturer’s instructions. To calculate the translucency parameter (TP), CIELAB value was measured with a spectrophotometer on black and white backgrounds. To investigate the color masking abilities, background shades of A2, normal dentin, discolored dentin, and titanium were used. The color difference (ΔE) was calculated with the CIELAB values of A2 shade background as a reference compared with the values in the various backgrounds. One-way ANOVA and Bonferroni tests were conducted (P < .05).RESULTSThe TP values of zirconia specimens increased as the yttria content increased. All materials used in the study were able to adequately mask normal dentin shade (ΔE < 5.5), but were incapable of masking severely discolored dentin (ΔE > 5.5). On the titanium background, all materials of 1.5 mm thickness were able to mask the background shade, but with a thickness of 0.8 mm, only 3Y-TZP and 4Y-PSZ were able to mask titanium background.CONCLUSIONAll zirconia materials and lithium disilicate specimens used in this study were unable to adequately mask the shade of severely discolored dentin. It is recommended to use 3Y-TZP or 4Y-PSZ with a sufficient thickness of 0.8 mm or more to mask titanium. 相似文献
63.
Dougho Park Jae-Hyun Yun Sungyoun Chun Byung-Mo Oh Hyoung Seop Kim 《Journal of Korean medical science》2022,37(32)
BackgroundPrevious studies have reported an association between pneumonia risk and the use of certain drugs. We investigated the relationship between antihypertensive drugs and pneumonia in the general population.MethodsThis case-crossover study utilized the nationwide data of South Korea. We included participants who were hospitalized for pneumonia. A single case period was defined as 30 days before pneumonia onset, and two control periods were established (90–120 and 150–180 days before pneumonia onset). Further, we performed sensitivity and subgroup analyses (according to the presence of diabetes, documented disability, and whether participants were aged ≥ 70 years). We used conditional logistic regression models adjusted for covariates, such as angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), other antihypertensives, statins, antipsychotics, benzodiazepine, and the number of outpatient visits.ResultsIn total, 15,463 subjects were included in this study. ACE inhibitors (adjusted odds ratio [aOR], 0.660; 95% confidence interval [CI], 0.558–0.781), ARBs (aOR, 0.702; 95% CI, 0.640–0.770), and other antihypertensive drugs (aOR, 0.737; 95% CI, 0.665–0.816) were significantly associated with reduced pneumonia risk. Subgroup analyses according to the presence of diabetes mellitus, documented disability, and whether participants were aged ≥ 70 years consistently showed the association of antihypertensives with a reduced risk of hospitalization for pneumonia.ConclusionAll antihypertensive drug types were related to a lower risk of hospitalization for pneumonia in the general population. Our results implied that frequent medical service usage and protective immunity were primarily related to a reduced risk of pneumonia in the general population of South Korea. 相似文献
64.
Kitae Kim Seung-Ah Lee Hong Rae Kim Jae Suk Yoo Joon Bum Kim Suk Jung Choo Cheol Hyun Chung Jae Won Lee Sung-Ho Jung 《Journal of thoracic disease》2022,14(12):4624
BackgroundWe aimed to evaluate the long-term surgical outcomes of patients with hypertrophic obstructive cardiomyopathy and explore the risk factors for mortality, especially those related to atrial fibrillation.MethodsWe retrospectively reviewed 150 consecutive patients with hypertrophic obstructive cardiomyopathy who underwent surgical treatment between March 2003 and December 2020.ResultsFifty (33.3%, age 53.7±16.1 years) patients underwent isolated septal myectomy (SM), 79 (52.7%, age 52.3±12.6 years) underwent SM with mitral valve intervention (SM + MVI), and 21 (14.0%, age 57.1±13.5 years) underwent SM with mitral valve replacement (SM + MVR). Overall peak left ventricular outflow tract pressure gradient at rest was significantly decreased from 91.9±43.2 to 13.3±13.0 mmHg (P<0.0001). Survival rates were 96.7%, 89.1%, and 81.5% at 30 days, 5 years, and 10 years, respectively. Patients in the SM + MVI group survived longer than those in SM + MVR or isolated SM groups (94.1% vs. 75.4% vs. 88.0%, respectively, at 5 years, P=0.05). Patients with preoperative atrial fibrillation had a worse 5-year survival rate than those without atrial fibrillation (73.4% vs. 92.8%, respectively, P<0.001). Preoperative atrial fibrillation was an independent risk factor for late mortality in multivariable analysis. Notably, those whose atrial fibrillation was successfully eradicated by surgical ablation had a better 5-year survival rate than other patients (87.7% vs. 28.6%, respectively, P<0.001).ConclusionsSurgical outcomes in hypertrophic obstructive cardiomyopathy are favorable in the long-term, except in patients with preoperative atrial fibrillation. Therefore, intraoperative ablation for preoperative atrial fibrillation in hypertrophic obstructive cardiomyopathy should be actively considered to improve patient outcomes. 相似文献
65.
66.
67.
68.
Hakjun Hyun Min Joo Choi Jung Yeon Heo Yu Bin Seo Eliel Nham Jin Gu Yoon Hye Seong Ji Yun Noh Hee Jin Cheong Woo Joo Kim Ju-Yeon Choi Young Jae Lee Hye Won Lee Sung Soon Kim Byoungguk Kim Joon Young Song 《Journal of Korean medical science》2022,37(27)
BackgroundAs the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated.MethodThis prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-γ enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs.ResultsFifty participants aged ≥ 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 ± 3.0 U/mL at 3–4 weeks, 55.7 ± 2.4 U/mL at 5–8 weeks, and 81.3 ± 2.5 U/mL at 10–12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 ± 4.6 at 3-4 weeks, 313.9 ± 3.6 at 5–8 weeks, and 124.4 ± 2.6 at 10–12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0–29.2) at baseline, 60.0 (23.3–178.3) at 5-8 weeks, and 35.0 (13.3–71.7) at 10–12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1–2, and resolved within two days.ConclusionSingle-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5–8 weeks and rather decrease at 10–12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible. 相似文献
69.
Yoon Jin Choi Yong Chan Lee Jung Mogg Kim Jin Il Kim Jeong Seop Moon Yun Jeong Lim Gwang Ho Baik Byoung Kwan Son Hang Lak Lee Kyoung Oh Kim Nayoung Kim Kwang Hyun Ko Hye-Kyung Jung Ki-Nam Shim Hoon Jai Chun Byung-Wook Kim Hyuk Lee Jie-Hyun Kim Hyunsoo Chung Sang Gyun Kim Jae Young Jang 《Gut and liver》2022,16(4):535
Background/AimsWe examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.MethodsA randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.ResultsIn total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.ConclusionsTPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier ). NCT03317223相似文献
70.
Su Jin Jeong Jinho Lee Eunju Kim Jun Seong Hwang Jin Lee Joon Hyuk Choi Nae-Yun Heo Jongha Park Seung Ha Park Tae Oh Kim Yong Eun Park 《Medicine》2022,101(27)
Colorectal cancer is a common cancer; generally, adults aged ≥ 50 years are screened using stool occult blood tests and colonoscopy. However, colorectal adenoma and cancer have been found in patients under the aged of 50, and studies on characteristics and risk factors in young patients are lacking. We evaluated the prevalence and risk factors of colorectal adenoma and cancer in young adults aged under 50 years.We retrospectively analyzed 570 individuals aged under 50 years who underwent colonoscopy at the Haeundae Paik Hospital, Korea, from January to June 2018. Logistic regression model was used to identify the risk factors for colorectal adenoma and colorectal cancer.The prevalence of colorectal adenoma in group of 19–29 years was 3.2% (1 of 31), 30–39 years was 13.8% (30 of 217) and in the group of 40–49 years was 21.1% (68 of 322) (P = .009). In multivariable analysis, age over 45 years (adjusted odds ratio [OR], 1.941; 95% confidence interval [CI], 1.187–3.172; P = .008) and male sex (adjusted OR, 1.711; 95% CI, 1.044–2.806; P = .033) were independent risk factors for colorectal neoplasia including cancer.The prevalence of colorectal adenoma increases as the age increased in young adults under 50 years of age, especially after the age of 45 years, the risk of colorectal neoplasia increases; hence, early screening should be considered before the age of 50 years. 相似文献